Antiangiogenic therapy in the management of brain tumors: A clinical overview

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 3, 2012, Pages 353-363

  Kunnakkat, Saroj ^a   Mathew, Maya ^a   Narayana, Ashwatha ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Brain tumor; Glioma; Invasion

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CILENGITIDE; ERLOTINIB; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; OLARATUMAB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PLATINUM COMPLEX; RAMUCIRUMAB; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASEMENT MEMBRANE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CONVULSION; DEACETYLATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; EPILEPSY; FATIGUE; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HEART VENTRICLE TACHYCARDIA; HEMIPARESIS; HUMAN; HYPERTENSION; INTESTINE PERFORATION; JAW OSTEONECROSIS; LONG QT SYNDROME; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MEGALOCYTOSIS; MELANOMA; MENINGIOMA; NAUSEA; NEURILEMOMA; NONHUMAN; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; VOMITING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866370183     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1926-7     Document Type: Review

References (78)

1. Fidler IJ (1999) Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmaco 43:S3-S10 (Pubitemid 29244626)
2. Jiménez B, Volpert OV (2001) Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 78(12):663-672
3. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027 (Pubitemid 46202320)
4. Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19(10):2003-2012 (Pubitemid 47354167)
5. Bautch VL, Redick SD, Scalia A, Harmaty M, Carmeliet P, Rapoport R (2000) Characterization of the vasculogenic block in the absence of vascular endothelial growth factor-A. Blood 95(6): 1979-1987 (Pubitemid 30151635)
6. Fong G-H, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376(6535):66-70
7. Shalaby F, Rossant J, Yamaguchi TP et al (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535):62-66
8. Zagzag D, Amirnovin R, Greco MA et al (2000) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80(6):837-849 (Pubitemid 30421801)
9. Zagzag D, Lukyanov Y, Lan L et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12):1221-1232 (Pubitemid 44789912)
10. Vredenburgh J, Desjardins A, Herndon J et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729 (Pubitemid 350086473)
11. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
12. Nghiemphu PL, Liu W et al (2009) Bevacizumab and chemotherapy for recurrent glioblastoma. Neurology 72(14):1217-1222
13. Kerber M, Reiss Y et al (2008) Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68(18):7342-7351
14. Geng L, Donnelly E et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61(6):2413-2419 (Pubitemid 32685816)
15. Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93(2):109-117 (Pubitemid 27060902)
16. Caye-Thomasen P et al (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. [Miscellaneous Article]. Otol Neurotol 26(1):98-101 (Pubitemid 40130217)
17. Hoch RV, Soriano P (2003) Roles of PDGF in animal development. Development 130(20):4769-4784 (Pubitemid 37321862)
18. Andrae J, Gallini R et al (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276-1312 (Pubitemid 351717519)
19. Charles N, Ozawa T et al (2010) Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGFinduced glioma cells. Cell Stem Cell 6(2):141-152
20. Lokker NA, Sullivan CM et al (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells. Cancer Res 62(13):3729-3735
21. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673-687 (Pubitemid 35283958)
22. Zhong J, Paul A et al (2010) Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol 2010(21):430142
23. Kanamori M, Kawaguchi T et al (2006) Intracranial microenvironment reveals independent opposing functions of host αVβ3 expression on glioma growth and angiogenesis. J Biol Chem 281(48):37256-37264 (Pubitemid 46042194)
24. Schnell O, Krebs B et al (2008) Expression of integrin avb3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Patho 18(3):378-386 (Pubitemid 351782847)
25. Puduvalli V (2001) Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 3(6):467-475
26. Weber GF, Ashkar S (2000) Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. Brain Res Bull 53(4):421-424 (Pubitemid 32000819)
27. Ouaissi M, Ouaissi A (2006) Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006:13474
28. Campos B, Bermejo JL et al (2011) Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102(2):387-392
29. Sharma V, Koul N et al (2010) HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med 14(8):2151-2161
30. Thudi NK, Shu ST et al (2011) Development of a brain metastatic canine prostate cancer cell line. Prostate 71(12):1251-1263
31. Vredenburgh JJ, Desjardins A et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259 (Pubitemid 46424067)
32. Kreisl TN, Kim L et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740-745
33. Narayana A, Kelly P et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurgery 110(1):173-180
34. Norden AD, Young GS et al (2008) Bevacizumab for recurrent malignant gliomas. Neurology 70(10):779-787
35. Lai A, Tran A et al (2011) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29(2): 142-148
36. Narayana A, Golfinos JG et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Rad Oncol Biol Phys 72(2): 383-389
37. Vredenburgh JJ, Desjardins A et al (2012) Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Rad Oncol Biol Phys 82(1):58-66
38. Narayana A, Gruber D et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurgery 116(2):341-345
39. Chamberlain MC, Johnston S (2009) Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115(8): 1734-1743
40. Mautner V-F, Nguyen R et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncol 12(1):14-18
41. Plotkin SR, Stemmer-Rachamimov AO et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358-367
42. Mautner V-F, Nguyen R et al (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21(11):2294-2295
43. Puchner MJA, Hans VH et al (2010) Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 21(12):2445-2446
44. Goutagny S, Raymond E et al (2011) Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 22(4):990-991
45. Socinski MA, Langer CJ et al (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27(31):5255-5261
46. Labidi SI, Bachelot T et al (2009) Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 9(2):118-121
47. Wong ET, Huberman M et al (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26(34):5649-5650
48. Torcuator R, Zuniga R et al (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neuro-Oncol 94(1):63-68
49. Spratlin JL, Mulder KE et al (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Fut Oncol 6(7):1085-1094
50. Spratlin JL, Cohen RB et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780-787
51. Farrar CT, Kamoun WS et al (2011) Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PLoS One 6(3):e17228
52. Dietrich J, Wang D et al (2009) Cediranib: profile of a novel antiangiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 18(10):1549-1557
53. Batchelor TT, Duda DG et al (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817-2823
54. Wachsberger PR, Lawrence YR et al (2012) Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. Int J Rad Oncol Biol Phys 82(1):483-491
55. Siegelin MD, Raskett CM et al (2010) Sorafenib exerts antiglioma activity in vitro and in vivo. Neurosci Lett 478(3): 165-170
56. Navis AC, Hamans BC et al (2011) Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. The J Pathol 223(5):626-634
57. Neyns B, Sadones J et al (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neuro-Oncol 103(3):491-501
58. Hainsworth JD, Ervin T et al (2010) Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15):3663-3669
59. Yoshikawa A, Nakada M et al (2012) Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics. Neuropathol Appl Neurobiol 38(1):105-110
60. Amaravadi RK, Schuchter LM et al (2009) Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 15(24):7711-7718
61. Gore ME, Hariharan S et al (2011) Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3): 501-509
62. Wuthrick EJ, Kamrava M et al (2011) A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 117(24):5548-5559
63. Maurer GD, Tritschler I et al (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncol 11(6):747-756
64. Reardon DA, Fink KL et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610-5617
65. Stupp R, Hegi ME et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712-2718
66. Sawa H, Murakami H et al (2004) Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 107(6):523-531 (Pubitemid 38765394)
67. Iwamoto FM, Lamborn KR et al (2011) A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American brain tumor consortium study 03-03. Neuro-Oncol 13(5):509-516
68. Berg SL, Stone J et al (2004) Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol 54(1):85-88 (Pubitemid 38858370)
69. Hariharan S, Gustafson D et al (2007) Assessment of the biological and pharmacological effects of the amb3 and amb5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18(8):1400-1407 (Pubitemid 47305015)
70. Shah MH, Binkley P et al (2006) Cardio toxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12(13):3997-4003 (Pubitemid 44078086)
71. Rini BI, Choueiri TK et al (2008) Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113(6): 1309-1314
72. Brunello A, Saia G et al (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44(1):173-175
73. Bergers G, Hanahan D (2008) Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8(8):592-603
74. Lucio-Eterovic AK, Piao Y et al (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15(14):4589-4599
75. de Groot JF, Fuller G et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncol 12(3):233-242
76. Iwamoto FM, Abrey LE et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15):1200-1206
77. Narayana A, Kunnakkat SD et al (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Rad Oncol Biol Phys 82(1):77-82
78. Wen PY, Macdonald DR et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972